Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a randomized placebo-controlled dose-ranging study of PTC518 in Huntington's disease
2021-003852-18Phase 2Active
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of votoplam in Huntington disease (HD) (4 arms), sponsored by PTC Therapeutics, Inc. Primary endpoints: Safety endpoints and Pharmacodynamic endpoints. Started Feb 2022; status: active.
02
Drugs
votoplam
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on 2021-003852-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003852-18.